Want to see AU:OCC full AI Analyst Report?
Top Page
Orthocell Ltd
(Sydney:OCC)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.76
▼(-6.30% Downside)
Action:Reiterated
Date:11/19/25
Orthocell Ltd faces significant challenges with profitability and cash flow, as reflected in its financial performance score. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
Sustained top-line expansion (annual growth reported) indicates underlying demand for products and/or improving commercial traction. Over a 2-6 month horizon, continued revenue growth supports scaling, investor confidence in product-market fit and funds incremental R&D or market expansion even if profits lag.
Negative Factors
Profitability Pressure
Persistent negative margins and a falling gross margin reflect structural cost pressures or pricing limits versus product costs. Over the medium term this undermines the ability to turn revenue growth into sustainable profits without material margin improvement, cost discipline, or higher-value product mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line expansion (annual growth reported) indicates underlying demand for products and/or improving commercial traction. Over a 2-6 month horizon, continued revenue growth supports scaling, investor confidence in product-market fit and funds incremental R&D or market expansion even if profits lag.
Read all positive factors
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$231.42M
Dividend YieldN/A
Average Volume (3M)820.75K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth49.03%
EPS Growth-232.68%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,253,630
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.26Price Target Upside55.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$22.80M
Orthocell Ltd Business Overview & Revenue Model
Company Description
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are desig...
How the Company Makes Money
Orthocell makes money primarily by commercialising its medical products and related services. Key revenue streams include: (1) Product sales: Sales of its nerve repair product Remplir to hospitals/clinicians and/or through distribution partners, g...
Orthocell Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.50M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -15.31M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -12.48M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 59.80M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 44.37M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 835.79K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 18.64M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 41.16M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -12.05M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -42.26M | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 30.84M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Neutral
0.81
Price Trends
0.79
Positive
0.82
Negative
0.96
Negative
Market Momentum
0.02
Negative
51.72
Neutral
62.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Neutral. The current price of 0.81 is above the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.79, and below the 200-day MA of 0.96, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.72 is Neutral, neither overbought nor oversold. The STOCH value of 62.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:OCC.
Orthocell Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$3.04B | -23.10 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$11.07M | -2.28 | -218.76% | ― | 76.94% | 42.95% | |
44 Neutral | AU$6.65M | -1.73 | -29.91% | ― | 82.28% | 13.33% | |
43 Neutral | AU$25.34M | 25.00 | -49.25% | ― | ― | 25.00% | |
41 Neutral | AU$231.42M | -15.23 | -44.80% | ― | 49.03% | -232.68% | |
41 Neutral | AU$3.41M | -0.35 | -179.37% | ― | ― | 24.59% |
* Healthcare Sector Average
AU:OCC
Orthocell Ltd
0.80
-0.43
-35.37%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.14
-91.33%
AU:1AI
Living Cell Technologies
0.01
<0.01
20.00%
AU:MSB
Mesoblast Limited
2.38
0.68
40.00%
AU:TRP
Tissue Repair Ltd
0.11
-0.12
-52.17%
AU:CMB
Regeneus Ltd.
0.41
0.14
50.00%
Orthocell Ltd Corporate Events
Orthocell Issues Cautious Q4 FY26 Investor Presentation Disclaimer
Jul 13, 2026
Orthocell has released a Q4 FY26 investor presentation outlining information intended for potential investors, while emphasising that the document is confidential and does not constitute an offer or solicitation to buy or sell securities. The comp...
Orthocell hits record revenue as Remplir adoption accelerates and global rollout advances
Jul 12, 2026
Orthocell reported record quarterly revenue of $3.8 million and full-year FY2026 revenue of $13.2 million, driven by accelerating adoption of its Remplir nerve repair device and Striate+ worldwide. The company highlighted a three-year trajectory o...
Orthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir
Jul 5, 2026
Orthocell Ltd has scheduled the release of its quarterly results for 13 July 2026 and will host an investor webinar on 14 July 2026 to present its financial performance and provide an operational update. Senior executives, including the chair, CEO...
Orthocell Expands Humanitarian Use of Remplir Nerve Repair Device in Ukraine
Jun 29, 2026
Orthocell has expanded the humanitarian deployment of its Remplir nerve repair device in Ukraine, as surgeons report strong clinical utility in treating complex battlefield and civilian trauma, including severe peripheral nerve injuries from amput...
Orthocell issues new shares after employee option exercise under equity incentive plan
May 5, 2026
Orthocell Limited has issued 445,696 fully paid ordinary shares following the cashless exercise of 1,050,000 employee options under its Employee Equity Incentive Scheme, priced at $0.515 per option and expiring in May 2026. The company has lodged ...
Orthocell Seeks ASX Quotation for 445,696 New Shares
May 5, 2026
Orthocell Ltd has lodged an application with the ASX for quotation of additional ordinary fully paid shares, identified under ticker OCC. The filing details the issuance of 445,696 new shares on 5 May 2026, arising from the exercise or conversion ...
Orthocell logs first Remplir sales in Canada, advancing global nerve repair rollout
Apr 30, 2026
Orthocell has recorded its first commercial sales of Remplir in Canada, following Health Canada approval and the appointment of distributors that provide majority national coverage in a nerve repair market worth about US$75 million. The company ha...
Orthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study
Apr 27, 2026
Orthocell has reported new real-world evidence showing its Remplir nerve repair device achieved an overall treatment success rate of 89.7% across 78 procedures in 66 patients, with no post-treatment complications or adverse effects recorded. The s...
Orthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing
Apr 19, 2026
Orthocell Ltd, a regenerative medicine and medical technology company specialising in cell-based therapies for musculoskeletal and nerve repair, targets clinicians and healthcare providers seeking advanced orthopaedic and reconstructive treatment ...
Orthocell records first U.S. military hospital case for Remplir after DoD–VA approval
Apr 16, 2026
Orthocell has completed the first U.S. Department of Defense and Veterans Affairs surgical case using its Remplir nerve repair product, just days after gaining approval to supply it across those hospital networks. The procedure, performed at a mil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.